Quercetin supplementation does not alter antioxidant status in humans

Free Radical Research

Volumn 44, Issue 2, 2010, Pages 224-231

  Shanely, R Andrew ^a   Knab, Amy M ^a   Nieman, David C ^a   Jin, Fuxia ^a   McAnulty, Steven R ^a   Landram, Michael J ^a  

^a APPALACHIAN STATE UNIVERSITY   (United States)

Author keywords

Antioxidant; F2 isoprostanes; Ferric reducing ability of plasma (FRAP); Glutathione; Oxidative stress; Oxidized low density lipoprotein (LDL); Oxygen radical absorbance capacity (ORAC); Quercetin

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; GLUCOSE TRANSPORTER; GLUTATHIONE; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; OXYGEN RADICAL; PLACEBO; QUERCETIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; QUERCETIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74549156348     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715760903407293     Document Type: Article

References (61)

1. Nutrient Data Laboratory (US); Food Composition Laboratory (US). USDA database for the fl avonoid content of selected foods. Beltsville, MD: US Department of Agriculture, Agricultural Research Service, Beltsville Human Nutrition Research Center, Nutrient Data Laboratory; 2007: ii, 128 p.
2. Sampson L, Rimm E, Hollman PC, de Vries JH, Katan MB. Flavonol and fl avone intakes in US health professionals. J Am Diet Assoc 2002;102:1414-1420.
3. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioeffi cacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005;81:230S-242S.
4. Ciz M, Pavelkova M, Gallova L, Kralova J, Kubala L, Lojek A. The infl uence of wine polyphenols on reactive oxygen and nitrogen species production by murine macro-phages RAW 264.7. Physiol Res 2008;57:393-402.
5. Dias AS, Porawski M, Alonso M, Marroni N, Collado PS, Gonzalez-Gallego J. Quercetin decreases oxidative stress, NF-kappaB activation, and iNOS overexpression in liver of streptozotocin-induced diabetic rats. J Nutr 2005;135:2299-2304.
6. Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Galvez J, Zarzuelo A. In vivo quercitrin anti-infl ammatory effect involves release of quercetin, which inhibits infl ammation through down-regulation of the NF-kappaB pathway. Eur J Immunol 2005;35:584-592.
7. Nair MP, Mahajan S, Reynolds JL, Aalinkeel R, Nair H, Schwartz SA, Kandaswami C. The fl avonoid quercetin inhibits proinfl ammatory cytokine (tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-kappa beta system. Clin Vaccine Immunol 2006;13:319-328.
8. Comalada M, Ballester I, Bailon E, Sierra S, Xaus J, Galvez J, de Medina FS, Zarzuelo A. Inhibition of pro-infl ammatory markers in primary bone marrow-derived mouse macro-phages by naturally occurring fl avonoids: analysis of the structure-activity relationship. Biochem Pharmacol 2006;72: 1010-1021.
9. Chiang LC, Chiang W, Liu MC, Lin CC. In vitro antiviral activities of Caesalpinia pulcherrima and its related fl avonoids. J Antimicrob Chemother 2003;52:194-198.
10. Vrijsen R, Everaert L, Boeye A. Antiviral activity of fl avones and potentiation by ascorbate. J Gen Virol 1988;69: 1749-1751.
11. Dimova S, Mugabowindekwe R, Willems T, Brewster ME, Noppe M, Ludwig A, Jorissen M, Augustijns P. Safety-assessment of 3-methoxyquercetin as an antirhinoviral compound for nasal application: effect on ciliary beat frequency. Int J Pharm 2003;263:95-103.
12. Chen L, Li J, Luo C, Liu H, Xu W, Chen G, Liew OW, Zhu W, Puah CM, Shen X, Jiang H. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features. Bioorg Med Chem 2006;14:8295-8306.
13. Davis JM, Murphy EA, McClellan JL, Carmichael MD, Gangemi JD. Quercetin reduces susceptibility to infl uenza infection following stressful exercise. Am J Physiol Regul Integr Comp Physiol 2008;295:R505-509.
14. Cushnie TP, Lamb AJ. Antimicrobial activity of fl avonoids. Int J Antimicrob Agents 2005;26:343-356.
15. Neuhouser ML. Dietary fl avonoids and cancer risk: evidence from human population studies. Nutr Cancer 2004;50:1-7.
16. Erdman JW, Balentine D, Arab L, Beecher G, Dwyer JT, Folts J, Harnly J, Hollman P, Keen CL, Mazza G, Messina M, Scalbert A, Vita J, Williamson G, Burrowes J. Flavonoids and heart health: Proceedings of the ILSI North America Flavonoids Workshop. Washington, DC: J Nutr 2005;137: 718S-737S.
17. Davis JM, Murphy EA, Carmichael MD, Davis B. Quercetin increases brain and muscle mitochondrial biogenesis and exercise tolerance. Am J Physiol Regul Integr Comp Physiol 2009;296:R1071-1077.
18. Chun OK, Chung SJ, Song WO. Estimated dietary fl avonoid intake and major food sources of U.S. adults. J Nutr 2007; 137:1244-1252.
19. Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G, Mueller MJ. Daily quer-cetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 2008;138:1615-1621.
20. Moon YJ, Wang L, DiCenzo R, Morris ME. Quercetin phar-macokinetics in humans. Biopharm Drug Dispos 2008;29: 205-217.
21. de Boer VC, Dihal AA, van der Woude H, Arts IC, Wolffram S, Alink GM, Rietjens IM, Keijer J, Hollman PC. Tissue distribution of quercetin in rats and pigs. J Nutr 2005;135: 1718-1725.
22. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007;45:2179-2205.
23. Utesch D, Feige K, Dasenbrock J, Broschard TH, Harwood M, Danielewska-Nikiel B, Lines TC. Evaluation of the potential in vivo genotoxicity of quercetin. Mutat Res 2008; 654:38-44.
24. Chopra M, Fitzsimons PE, Strain JJ, Thurnham DI, Howard AN. Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. Clin Chem 2000;46:1162-1170.
25. Nieman DC, Henson DA, Maxwell KR, Williams AS, McAnulty SR, Jin F, Shanely RA, Lines TC. Effects of quercetin and EGCG on mitochondrial biogenesis and immunity. Med Sci Sports Exerc 2009;41:1467-1475.
26. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, Jacobs DR, Jr. Flavonoid intake and cardiovascular disease mortality: a prospective study in post-menopausal women. Am J Clin Nutr 2007;85:895-909.
27. Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, Hakulinen T, Aromaa A. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002;76:560-568.
28. Duenas M, Gonzalez-Manzano S, Gonzalez-Paramas A, Santos-Buelga C. Antioxidant evaluation of O-methylated metabolites of catechin, epicatechin and quercetin. J Pharm Biomed Anal 2009;51:443-449.
29. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of fl avonoids and phenolic acids. Free Radic Biol Med 1996;20:933-956.
30. Hou L, Zhou B, Yang L, Liu ZL. Inhibition of human low density lipoprotein oxidation by fl avonols and their glycosides. Chem Phys Lipids 2004;129:209-219.
31. Loke WM, Proudfoot JM, McKinley AJ, Needs PW, Kroon PA, Hodgson JM, Croft KD. Quercetin and its in vivo metabolites inhibit neutrophil-mediated low-density lipoprotein oxidation. J Agric Food Chem 2008;56:3609-3615.
32. Justino GC, Santos MR, Canario S, Borges C, Florencio MH, Mira L. Plasma quercetin metabolites: structure-antioxidant activity relationships. Arch Biochem Biophys 2004;432: 109-121.
33. Erden Inal M, Kahraman A. The protective effect of fl avonol quercetin against ultraviolet a induced oxidative stress in rats. Toxicology 2000;154:21-29.
34. Gong M, Garige M, Varatharajalu R, Marmillot P, Gottipatti C, Leckey LC, Lakshman RM. Quercetin up-regulates paraoxo-nase 1 gene expression with concomitant protection against LDL oxidation. Biochem Biophys Res Commun 2009;379: 1001-1004.
35. Coskun O, Kanter M, Korkmaz A, Oter S. Quercetin, a fl avonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res 2005;51:117-123.
36. Moon JH, Tsushida T, Nakahara K, Terao J. Identifi cation of quercetin 3-O-beta-D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin. Free Radic Biol Med 2001;30:1274-1285.
37. Egert S, Bosy-Westphal A, Seiberl J, Kurbitz C, Settler U, Plachta-Danielzik S, Wagner AE, Frank J, Schrezenmeir J, Rimbach G, Wolffram S, Muller MJ. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr 2009;102: 1065-1074.
38. Beatty ER, O'Reilly JD, England TG, McAnlis GT, Young IS, Geissler CA, Sanders TA, Wiseman H. Effect of dietary quer-cetin on oxidative DNA damage in healthy human subjects. Br J Nutr 2000;84:919-925.
39. Boyle SP, Dobson VL, Duthie SJ, Hinselwood DC, Kyle JA, Collins AR. Bioavailability and effi ciency of rutin as an anti-oxidant: a human supplementation study. Eur J Clin Nutr 2000;54:774-782.
40. Quindry JC, McAnulty SR, Hudson MB, Hosick P, Dumke C, McAnulty LS, Henson D, Morrow JD, Nieman D. Oral quercetin supplementation and blood oxidative capacity in response to ultramarathon competition. Int J Sport Nutr Exerc Metab 2008;18:601-616.
41. Boots AW, Wilms LC, Swennen EL, Kleinjans JC, Bast A, Haenen GR. In vitro and ex vivo anti-infl ammatory activity of quercetin in healthy volunteers. Nutrition 2008;24:703-710.
42. Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T. Quercetin reduces blood pressure in hypertensive subjects. J Nutr 2007;137:2405-2411.
43. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 2008;10:1405-1434.
44. Morrow JD. Quantifi cation of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005;25:279-286.
45. Voss P, Siems W. Clinical oxidation parameters of aging. Free Radic Res 2006;40:1339-1349.
46. McAnulty SR, McAnulty LS, Nieman DC, Quindry JC, Hosick PA, Hudson MH, Still L, Henson DA, Milne GL, Morrow JD, Dumke CL, Utter AC, Triplett NT, Dibarnardi A. Chronic quercetin ingestion and exercise-induced oxidative damage and infl ammation. Appl Physiol Nutr Metab 2008;33:254-262.
47. Morrow JD, Roberts LJ, 2nd. Mass spectrometric quanti-fication of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol 1999;300:3-12.
48. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, Collen D. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996;76: 663-669.
49. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR, Jr. Association between circulating oxidized low-density lipopro-tein and incidence of the metabolic syndrome. JAMA 2008; 299:2287-2293.
50. Jozwik M, Szczypka M, Gajewska J, Laskowska-Klita T. Antioxidant defence of red blood cells and plasma in stored human blood. Clin Chim Acta 1997;267:129-142.
51. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of 'antioxidant power': the FRAP assay. Anal Biochem 1996;239:70-76.
52. Cao G, Alessio HM, Cutler RG. Oxygen-radical absorbance capacity assay for antioxidants. Free Radic Biol Med 1993; 14:303-311.
53. Loke WM, Hodgson JM, Proudfoot JM, McKinley AJ, Puddey IB, Croft KD. Pure dietary fl avonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am J Clin Nutr 2008;88: 1018-1025.
54. Lotito SB, Frei B. Consumption of fl avonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon? Free Radic Biol Med 2006;41: 1727-1746.
55. Loke WM, Proudfoot JM, Stewart S, McKinley AJ, Needs PW, Kroon PA, Hodgson JM, Croft KD. Metabolic transformation has a profound effect on anti-infl ammatory activity of fl avonoids such as quercetin: lack of association between antioxidant and lipoxygenase inhibitory activity. Biochem Pharmacol 2008;75:1045-1053.
56. Manach C, Morand C, Crespy V, Demigne C, Texier O, Regerat F, Remesy C. Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 1998;426:331-336.
57. Chen CY, Milbury PE, Chung SK, Blumberg J. Effect of almond skin polyphenolics and quercetin on human LDL and apolipoprotein B-100 oxidation and conformation. J Nutr Biochem 2007;18:785-794.
58. Moon YJ, Morris ME. Pharmacokinetics and bioavailability of the biofl avonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in rats. Mol Pharm 2007;4:865-872.
59. Camuesco D, Comalada M, Concha A, Nieto A, Sierra S, Xaus J, Zarzuelo A, Galvez J. Intestinal anti-infl ammatory activity of combined quercitrin and dietary olive oil supplemented with fi sh oil, rich in EPA and DHA (n-3) polyun-saturated fatty acids, in rats with DSS-induced colitis. Clin Nutr 2006;25:466-476.
60. Mostafavi-Pour Z, Zal F, Monabati A, Vessal M. Protective effects of a combination of quercetin and vitamin E against cyclosporine A-induced oxidative stress and hepatotoxicity in rats. Hepatol Res 2008;38:385-392.
61. Ivanov V, Cha J, Ivanova S, Kalinovsky T, Roomi MW, Rath M, Niedzwiecki A. Essential nutrients suppress infl ammation by modulating key infl ammatory gene expression. Int J Mol Med 2008;22:731-741.